International Journal of Internal Medicine

Non-valvular atrial fibrillation is a common arrhythmia disease in China and even in the world so far. The incidence rate gradually increases with the age of the patients. Atrial fibrillation occurs in the 30-85-year-old group in China. The probability of atrial fibrillation is about 0.77%, and the probability of atrial fibrillation in elderly patients over 80 years old is higher than 30%. Patients with atrial fibrillation often lead to death or disability due to stroke, so patients with atrial fibrillation need long-term anticoagulation. Treatment to reduce the risk of death or disability. The effective measures to reduce the occurrence of stroke in patients with non-valvular atrial fibrillation are usually the use of oral anticoagulants. In recent years, with the continuous improvement and improvement of pharmaceutical technology, the advent of indobufen has increased the number of non-valvular atrial fibrillation patients for clinicians. As well as the choice of anticoagulant drugs for patients after PCI, clinicians can formulate appropriate anticoagulant drug use plans for patients based on their own clinical experience and the needs of patients. It describes the clinical efficacy of patients with non-valvular atrial fibrillation.

Indobufen; Anticoagulation; Therapeutic effect; Atrial fibrillation